scholarly journals Magneto-Liposomes as MRI Contrast Agents: A Systematic Study of Different Liposomal Formulations

Nanomaterials ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 889 ◽  
Author(s):  
Nina Kostevšek ◽  
Calvin C. L. Cheung ◽  
Igor Serša ◽  
Mateja Erdani Kreft ◽  
Ilaria Monaco ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Lipid Bilayer ◽  
Mri Contrast Agents ◽  
Mri Contrast ◽  
Liposomal Formulations ◽  
Icp Ms ◽  
Magnetic Resonance Imaging Mri ◽  
Cancerous Cells ◽  
Selection Of

The majority of the clinically approved iron oxide nanoparticles (IO NPs) used as contrast agents for magnetic resonance imaging (MRI) have been withdrawn from the market either due to safety concerns or lack of profits. To address this challenge, liposomes have been used to prepare IO-based T2 contrast agents. We studied the influence of different phospholipids on the relaxivity (r2) values of magneto-liposomes (MLs) containing magnetic NPs in the bilayer, where a strong correlation between the bilayer fluidity and r2 is clearly shown. Embedding 5-nm IO NPs in the lipid bilayer leads to a significant improvement in their relaxivity, where r2 values range from 153 ± 5 s−1 mM−1 for DPPC/cholesterol/DSPE-PEG (96/50/4) up to 673 ± 12 s−1 mM−1 for DOPC/DSPE-PEG (96/4), compared to “free” IO NPs with an r2 value of 16 s−1 mM−1, measured at 9.4 T MRI scanner. In vitro MRI measurements, together with the ICP-MS analysis, revealed MLs as highly selective contrast agents that were preferentially taken up by cancerous T24 cells, which led to an improvement in the contrast and an easier distinction between the healthy and the cancerous cells. A careful selection of the lipid bilayer to prepare MLs could offer efficient MRI contrast agents, even at very low IO NP concentrations.

scholarly journals Genetic encoding of targeted MRI contrast agents for in vivo tumor imaging

2019 ◽  
Author(s):  
Simone Schuerle ◽  
Maiko Furubayashi ◽  
Ava P. Soleimany ◽  
Tinotenda Gwisai ◽  
Wei Huang ◽  
...  
Keyword(s):  
Magnetic Nanoparticles ◽  
Contrast Agents ◽  
Tumor Imaging ◽  
Mri Contrast Agents ◽  
Contrast Effects ◽  
Mri Contrast ◽  
Magnetic Resonance Imaging Mri ◽  
Targeted Mri

AbstractTumor-selective contrast agents have the potential to aid in the diagnosis and treatment of cancer using noninvasive imaging modalities such as magnetic resonance imaging (MRI). Such contrast agents can consist of magnetic nanoparticles incorporating functionalities that respond to cues specific to tumor environments. Genetically engineering magnetotactic bacteria to display peptides has been investigated as a means to produce contrast agents that combine the robust image contrast effects of magnetosomes with transgenic targeting peptides displayed on their surface. This work reports the first use of magnetic nanoparticles that display genetically-encoded pH low insertion peptide (pHLIP), a long peptide intended to enhance MRI contrast by targeting the extracellular acidity associated with the tumors. To demonstrate the modularity of this versatile platform to incorporate diverse targeting ligands by genetic engineering, we also incorporated the cyclic αv integrin-binding peptide iRGD into separate magnetosomes. Specifically, we investigate their potential for enhanced binding and tumor imaging both in vitro and in vivo. Our experiments indicate that these tailored magnetosomes retain their magnetic properties, making them well-suited as T2 contrast agents, while exhibiting increased binding compared to wild-type magnetosomes.

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

2021 ◽  
Author(s):  
Anton Popov ◽  
Maxim Artemovich Abakumov ◽  
Irina Savintseva ◽  
Artem Ermakov ◽  
Nelly Popova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Selective Cytotoxicity ◽  
Magnetic Resonance Imaging Mri

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...

scholarly journals Study on Establishing Reference Safe Concentrations of MRI Contrast Agents for Optimized Images: Paramagnetic Gd-DTPA-BMEA and Superparamagnetic Ferucarbotran

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast Agent ◽  
In Vitro Experiments ◽  
Mri Contrast ◽  
In Vivo Experiments ◽  
Contrast Agent Injection

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.

Water-soluble magnetic CoO nanocrystals functionalized with surfactants as T2-weighed MRI contrast agents in vitro

2011 ◽  
Vol 40 (14) ◽  
pp. 3616 ◽  
Author(s):  
Hong Yang ◽  
Hong Zhou ◽  
Cuixia Zhang ◽  
Xuejian Li ◽  
He Hu ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Water Soluble ◽  
Mri Contrast

scholarly journals Effect of Gd and Dy Concentrations in Layered Double Hydroxides on Contrast in Magnetic Resonance Imaging

Processes ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 462 ◽  
Author(s):  
Karina Nava Andrade ◽  
Gregorio Guadalupe Carbajal Arízaga ◽  
José Antonio Rivera Mayorga
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Molar Ratios ◽  
Magnetic Resonance Imaging Mri ◽  
Double Hydroxide ◽  
Double Hydroxides

In this work, we explore the synthesis of layered double hydroxide (LDH) particles containing different molar ratios of Gd3+ and Dy3+ cations. A single crystalline phase was obtained for Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH, and their efficiency as contrast agents was evaluated by T1- and T2-weighted magnetic resonance imaging (MRI). Both GdDy-LDHs exhibited longitudinal relaxivity (r1) higher than a commercial reference. The highest contrast in the T1 mode was achieved with the Zn2.0Al0.75Gd0.125Dy0.125-LDH, which contained the lowest concentration of lanthanides; this efficiency is related to the lowest amount of carbonate anions complexing the lanthanide sites. On the contrary, the best contrast in the T2 mode was achieved with Zn2.0Al0.5Gd0.25Dy0.25-LDH. Zn2.0Al0.75Gd0.125Dy0.125-LDH and Zn2.0Al0.5Gd0.25Dy0.25-LDH presented r2/r1 ratios of 7.9 and 22.5, respectively, indicating that the inclusion of gadolinium and dysprosium into layered structures is a promising approach to the development of efficient bimodal (T1/T2) MRI contrast agents.

scholarly journals Ferritin: A Platform for MRI Contrast Agents Delivery

Inorganics ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 33 ◽  
Author(s):  
Maria Ruggiero ◽  
Diego Alberti ◽  
Valeria Bitonto ◽  
Simonetta Geninatti Crich
Keyword(s):  
Magnetic Resonance Imaging ◽  
Targeted Therapy ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Magnetic Resonance Imaging Mri ◽  
Accurate Imaging ◽  
Unique Surface

The search for high relaxivities and increased specificity continues to be central to the development of paramagnetic contrast agents for magnetic resonance imaging (MRI). Ferritin, due to its unique surface properties, architecture, and biocompatibility, has emerged as a natural nanocage that can potentially help to reach both these goals. This review aims to highlight recent advances in the use of ferritin as a nanoplatform for the delivery of metal-based MRI contrast agents (containing Gd3+, Mn2+, or Fe2O3) alone or in combination with active molecules used for therapeutic purposes. The collected results unequivocally show that the use of ferritin for contrast agent delivery leads to more accurate imaging of cancer cells and a significantly improved targeted therapy.

scholarly journals Uniform Fe3O4/Gd2O3-DHCA nanocubes for dual-mode magnetic resonance imaging

2020 ◽  
Vol 11 ◽  
pp. 1000-1009
Author(s):  
Miao Qin ◽  
Yueyou Peng ◽  
Mengjie Xu ◽  
Hui Yan ◽  
Yizhu Cheng ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Clinical Diagnostics ◽  
Resonance Imaging ◽  
Dual Mode ◽  
Mri Contrast ◽  
Magnetic Resonance Imaging Mri

The multimodal magnetic resonance imaging (MRI) technique has been extensively studied over the past few years since it offers complementary information that can increase diagnostic accuracy. Simple methods to synthesize contrast agents are necessary for the development of multimodal MRI. Herein, uniformly distributed Fe3O4/Gd2O3 nanocubes for T 1–T 2 dual-mode MRI contrast agents were successfully designed and synthesized. In order to increase hydrophilicity and biocompatibility, the nanocubes were coated with nontoxic 3,4-dihydroxyhydrocinnamic acid (DHCA). The results show that iron (Fe) and gadolinium (Gd) were homogeneously distributed throughout the Fe3O4/Gd2O3-DHCA (FGDA) nanocubes. Relaxation time analysis was performed on the images obtained from the 3.0 T scanner. The results demonstrated that r 1 and r 2 maximum values were 67.57 ± 6.2 and 24.2 ± 1.46 mM−1·s−1, respectively. In vivo T 1- and T 2-weighted images showed that FGDA nanocubes act as a dual-mode contrast agent enhancing MRI quality. Overall, these experimental results suggest that the FGDA nanocubes are interesting tools that can be used to increase MRI quality, enabling accurate clinical diagnostics.

Sign in / Sign up

Export Citation Format

Share Document